

Hyperammonemia

[View the current Hyperammonemia InDepth page on BioPortfolio.com](#) (PDF)

(<http://www.bioportfolio.com/indepth/Hyperammonemia.html>) - Regularly Updated.

Hyperammonemia is a metabolic disturbance characterised by an excess of ammonia in the blood. It is a dangerous condition that may lead to encephalopathy and death. It may be primary or secondary. Ammonia is a substance that contains nitrogen. It is a product of the catabolism of protein. It is converted to the less toxic substance urea prior to excretion in urine by the kidneys. The metabolic pathways that synthesise urea are located first in the mitochondria and then into the cytosol. The process is known as the urea cycle, which comprises several enzymes acting in sequence. ([From the Wikipedia article Hyperammonemia](#).)

Recent Publications on Hyperammonemia:



- [Generalized convulsion resulted in hyperammonemia during treatment with tranexamic acid for hemoptysis.](#)
BACKGROUND: Tranexamic acid is commonly used to treat various kinds of... 19th November, 2009
Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital,- Ir J Med Sci. 2009 Nov 17. ([DOI Direct Link](#))
- [A critical analysis of studies assessing L-ornithine-L-aspartate \(LOLA\) in hepatic encephalopathy treatment.](#)
CONTEXT: Experimental and clinical studies suggest that LOLA may have a... 18th November, 2009
Sao Paulo Center for Health Economics, CPES, Federal University of Sao- Arq Gastroenterol. 2009 Jul-Sep;46(3):241-7.
- [Hyperinsulinism-hyperammonemia syndrome: novel mutations in the GLUD1 gene and genotype-phenotype correlations.](#)
BACKGROUND: Activating mutations in the GLUD1 gene (which encodes for the... 17th November, 2009
Developmental Endocrinology Research Group, Molecular Genetics Unit,- Eur J Endocrinol. 2009 Nov;161(5):731-5. Epub 2009 Aug 18. ([DOI Direct Link](#))
- [AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis.](#)
Cytosolic enzymes AMP deaminase and adenosine deaminase (ADA) catalyze AMP... 11th November, 2009
Institute of Theoretical and Experimental Biophysics, Russian Academy of- Brain Res. 2009 Nov 10. ([DOI Direct Link](#))
- [On the reversibility of glutamate dehydrogenase and the source of hyperammonemia in the hyperinsulinism/hyperammonemia syndrome.](#)
Cytosolic enzymes AMP deaminase and adenosine deaminase (ADA) catalyze AMP... 10th November, 2009

- Buck Institute for Age Research, Novato, CA 94945, USA.- Adv Enzyme Regul. 2009 Nov 4. ([DOI Direct Link](#))
- [N-Carbamylglutamate in Emergency Management of Hyperammonemia in Neonatal Acute Onset Propionic and Methylmalonic Aciduria.](#)
*In propionic aciduria and methylmalonic aciduria, hyperammonemia as a...*6th November, 2009
Neonatal Intensive Care Unit, Department of Critical Care Medicine, A.- Neonatology. 2009 Nov 4;97(3):286-290. ([DOI Direct Link](#))
 - [Effect of the class I metabotropic glutamate receptor antagonist AIDA on certain behaviours in rats with experimental chronic hyperammonemia.](#)
*Purpose: This study examines possible interactions between behavioral...*31st October, 2009
Department of Pharmacology, Medical University of Bialystok, Bialystok,- Adv Med Sci. 2009 Oct 29;1-8. ([DOI Direct Link](#))
 - [Late-onset ornithine transcarbamylase deficiency: a potentially fatal yet treatable cause of coma.](#)
*Hyperammonaemia due to ornithine transcarbamylase (OTC) deficiency is a...*21st October, 2009
Department of Intensive Care Medicine, Austin Hospital, Melbourne, VIC.- Crit Care Resusc. 2009 Sep;11(3):222-7.
 - [Near fatal posterior reversible encephalopathy syndrome complicating chronic liver failure and treated by induced hypothermia and dialysis: a case report.](#)
*INTRODUCTION: Posterior reversible encephalopathy syndrome is a...*16th October, 2009
- J Med Case Reports. 2009 Mar 26;3:6623. ([DOI Direct Link](#))
 - [Acute encephalopathy of Bacillus cereus mimicking Reye syndrome.](#)
*We present an 11-year-old boy diagnosed as having acute encephalopathy and...*3rd October, 2009
Department of Pediatrics, Yokohama City University Medical Center,- Brain Dev. 2009 Sep 29. ([DOI Direct Link](#))
 - [New trends in surgical treatment for portal hypertension.](#)
*A number of surgical procedures have been developed to manage esophageal...*3rd October, 2009
Department of Surgery, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.- Hepatol Res. 2009 Oct;39(10):1044-51. ([DOI Direct Link](#))
 - [Highly variable clinical phenotype of carbamylphosphate synthetase 1 deficiency in one family: an effect of allelic variation in gene expression?](#)
*Deficiency of the urea cycle enzyme carbamylphosphate synthetase 1 (CPS1)...*2nd October, 2009
Universitätsklinikum Munster, Klinik und Poliklinik für Kinder- und- Clin Genet. 2009 Sep;76(3):263-9. ([DOI Direct Link](#))
 - [Valproic Acid-induced hyperammonemia in the elderly: a review of the literature.](#)
*Valproic acid and its derivatives are commonly used to treat many...*3rd September, 2009
Parkland Health Center, 1103 West Liberty Street, Farmington, MO 63640,- Case Report Med. 2009;2009:802121. Epub 2009 Aug 19. ([DOI Direct Link](#))
 - [Evidence that the major metabolites accumulating in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome induce oxidative stress in brain of young rats.](#)
*Ornithine and homocitrulline are the major metabolites accumulating in...*18th August, 2009
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde,- Int J Dev Neurosci. 2009 Nov;27(7):635-41. Epub 2009 Aug 13. ([DOI Direct Link](#))
 - [Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male.](#)
*Ornithine transcarbamylase (OTC) deficiency is an X-linked urea cycle...*12th August, 2009
Departments of Orofacial Sciences and Pediatrics, and Institute of Human- Hepatol Int. 2008 Sep;2(3):390-4. Epub 2008 May 7. ([DOI Direct Link](#))

BioNews Results for Hyperammonemia

- [Hyperion Therapeutics Announces First Patient Enrolled in Trial in Children with Urea Cycle Disorders](#)
Pharma Live: Sep 15 2009 10:08PM Matching: hyperammonemia



Hyperammonemia Patents:

- 6521225- [AAV vectors](#)
- 6855314- [AAV5 vector for transducing brain cells and lung cells](#)
- 6875792- [Dosage form of L-Methionine S-Sulfoximine](#)
- 6916490- [Controlled release of bioactive substances](#)
- 6984517- [AAV5 vector and uses thereof](#)
- 6989256- [Subfamily of RNA helicases which are modulators of the fidelity of translation termination and uses thereof](#)
- 6992064- [N-alkylglycine trimers capable of protecting neurons against excitotoxic aggressions and compositions containing such trimers](#)
- 7001371- [Porous drug delivery system](#)
- 7037304- [Implantable system for cell growth control](#)
- 7101565- [Probiotic/prebiotic composition and delivery method](#)
- 7115297- [Nutritionally fortified liquid composition with added value delivery systems/elements/additives](#)
- 6852707- [Remedies for hyperammonemia](#)
- 6835750- [Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II](#)
- 6524610- [Nutritional composition made from conventional foods for mixing onsite in a blender and treating patients with hepatic disorders](#)
- 6538030- [Treating radiation fibrosis](#)
- 6548302- [Polymers for delivery of nucleic acids](#)
- 6552074- [Arginine/ascorbic acid mixed powder as an oral supplement](#)
- 6573049- [Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease](#)
- 6630294- [Subfamily of RNA helicases which are modulators of the fidelity of translation termination and uses thereof](#)
- 6689795- [Methods for treating dementia due to HIV disease](#)
- 6734166- [Method of reducing aluminum levels in the central nervous system](#)
- 6743823- [Therapeutic methods relating to human carbamyl phosphate synthetase I polymorphism](#)
- 6809118- [Methods for therapy of radiation cutaneous syndrome](#)
- 7122172- [Methods and compositions for targeted drug delivery](#)
- 7132521- [Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress](#)
- 7148202- [Receptor-mediated gene delivery using bacteriophage vectors](#)
- 7433520- [Nosologic system of diagnosis](#)
- 7469185- [Primary rat hepatocyte toxicity modeling](#)
- 7479554- [AAV5 nucleic acids](#)
- 7485435- [Simultaneous detection of metabolic enzyme activity and metabolite levels](#)
- 7504227- [Drug targets for the treatment of neurodegenerative disorders](#)
- 7517686- [Dedifferentiated, programmable stem cells of monocytic origin, and their production and use](#)
- 7553663- [Dedifferentiated, programmable stem cells of monocytic origin, and their production and use](#)

- 7563458- [Nutritional compositions for nutritional management of patients with liver disease](#)
- 7563808- [Methods for treating cognitive impairments or dementia](#)
- 7613343- [Nosologic system of diagnosis](#)
- 7420044- [Nucleic acid and protein homologs and uses thereof](#)
- 7413850- [Uses of carbamoyl phosphate synthetase for the diagnosis of inflammatory diseases and sepsis](#)
- 7157497- [Method of enhancing an ornithine-urea cycle in ruminant gut tissues to detoxify ammonia and increase local urea recycling to the rumen for microbial protein synthesis](#)
- 7189891- [Isolated ferric reductase defective polypeptides and uses thereof](#)
- 7192933- [Use of a baculovirus to express an exogenous gene in a mammalian cell](#)
- 7214709- [Arginine/ascorbic acid mixed powder as an oral supplement](#)
- 7255874- [Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto](#)
- 7256202- [Composition and method for treatment of hepatic encephalopathy](#)
- 7279565- [Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress](#)
- 7291461- [Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay](#)
- 7338781- [Organic anion transporting \(oat\)-like protein UST3-LIKE1 and uses thereof](#)
- 7368527- [HADDE71 polypeptides](#)
- 7618793- [Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

